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ABSTRACT
Objective: To conduct a literature review on the diagnosis and management of primary hyper-
parathyroidism including the classical hipercalcemic form as well as the normocalcemic va-
riant. Materials and methods: This scientific statement was generated by a request from the 
Brazilian Medical Association (AMB) to the Brazilian Society for Endocrinology as part of its 
Clinical Practice Guidelines program. Articles were identified by searching in PubMed and Co-
chrane databases as well as abstracts presented at the Endocrine Society, Brazilian Society 
for Endocrinology Annual Meetings and the American Society for Bone and Mineral Research 
Annual Meeting during the last 5 years. Grading quality of evidence and strength of recommen-
dation were adapted from the first report of the Oxford Centre for Evidence-based Medicine. 
All grades of recommendation, including “D”, are based on scientific evidence. The differences 
between A, B, C and D, are due exclusively to the methods employed in generating evidence. 
Conclusion: We present a scientific statement on primary hyperparathyroidism providing the 
level of evidence and the degree of recommendation regarding causes, clinical presentation as 
well as surgical and medical treatment. Arq Bras Endocrinol Metab. 2013;57(6):406-24
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ReSumo
Objetivo: Conduzir uma atualização das últimas evidências científicas a respeito da apresenta-
ção, do diagnóstico e do manejo clínico e cirúrgico do hiperparatireoidismo primário clássico e 
normocalcêmico. Materiais e métodos: Este documento foi concebido pelo Departamento de 
Metabolismo Ósseo da Sociedade Brasileira de Endocrinologia e Metabologia (SBEM) a partir 
daquele oriundo do Programa de Diretrizes da Associação Médica Brasileira (AMB) da SBEM. 
Realizamos uma revisão dos artigos mais relevantes obtidos nos bancos de dados PubMed 
e Cochrane, além de abstracts apresentados nos encontros anuais da Endocrine Society, da 
Sociedade Brasileira de Endocrinologia e da American Society for Bone and Mineral Research 
dos últimos cinco anos, e classificamos as evidências em níveis de recomendações de acordo 
com a força científica por tipo de estudo, adaptando o primeiro relato do “Oxford Centre for 
Evidence-based Medicine”. Todos os graus de recomendação, incluindo-se o “D”, foram basea-
dos em evidência científica, sendo as diferenças entre o A, B, C e D devidas exclusivamente 
ao desenho empregado na geração da evidência. Conclusão: Apresentamos uma atualização 
científica a respeito do hiperparatireoidismo primário, classificando e graduando em níveis de 
recomendações as principais evidências científicas sobre as suas causas, as variadas formas de 
apresentação, seu diagnóstico e tratamento. Arq Bras Endocrinol Metab. 2013;57(6):406-24
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INTRoDuCTIoN
P rimary hyperparathyroidism (PHPT) is a disease caused by overactive parathyroid glands with con-
sequent hypercalcemia (1). The main cause in 85%-90% 
of cases, is the presence of a solitary parathyroid adeno-
ma (2,3). In the other affected patients, hyperplasia or 
multiple adenomas occur, the latter common in familial 
forms (3). PHPT occurs most commonly in individuals 
over 50 years of age and in postmenopausal women, 
showing a prevalence of about 0.78% in patients eva-
luated in reference services (4). Although the clinical 
presentation is variable the asymptomatic hypercalce-
mia form, detected by routine screening, is the most 
common (50% to 80%) (2). However, the presentation 
is variable, with patients demonstrating a range from 
normocalcemia to severe hypercalcemic PHPT (1).
meTHoDS
This scientific statement was generated by a request 
from the Brazilian Medical Association (AMB) to the 
Brazilian Society for Endocrinology as part of its Clini-
cal Practice Guidelines program. Through the Brazilian 
Society for Endocrinology’s Department of Bone Me-
tabolism, a task force was established. A draft of this re-
port was submitted for comment to the membership of 
the Brazilian Medical Association and Brazilian Society 
of Endocrinology. This report represents the comple-
tion of this process.
Grading quality of evidence and strength of recom-
mendation were adapted from the first report of the 
Oxford Centre for Evidence-Based Medicine, detailed 
described elsewhere (5) and summarized in table 1. 
Grades of recommendation are reported, as follows: 
A: more consistent experimental or observational 
trials.
B: less consistent experimental or observational 
trials.
C: case reports (non-controlled trials).
D: opinion without critical evaluation, based on con-
sensus, physiological studies or animal models.
Articles were identified by searching in PubMed 
and Cochrane databases as well as abstracts presented 
at the Endocrine Society and Brazilian Society for En-
docrinology Annual Meetings and the American So-
ciety for Bone and Mineral Research Annual Meeting 
during the last 5 years. References are listed numeri-
cally in order of appearance in the text, followed by the 
levels of evidence. 
Table 1. Grades of recommendation and strength scientific evidence 
A 1 A Systematic review of RCT*
Systematic reviews of prospective cohort studies
1 B Individual RCT* with narrow confidence interval
Prospective cohort studies
B 2 A Systematic review of retrospective cohort studies
2 B RCT* with > 20% dropout
Retrospective cohort studies
3 A Systematic review of case-control studies
3 B Individual case-control studies
C 4 Case series
D 5 Expert opinion 
* RCT: randomized controlled trials.
eTIoLoGY oF PRImARY HYPeRPARATHYRoIDISm
PHPT occurs due to unregulated and excessive para-
thyroid hormone (PTH) secretion by one or more pa-
rathyroid glands (1).
Solitary parathyroid adenomas represent about 
85% to 90% of PHPT cases (1,2) (C-4). In most other 
cases, multiple hyperfunctioning parathyroid glands 
occur, including hyperplasia and multiple adenomas 
(3,6) (C-4). Multiple gland disease is the most com-
mon finding in individuals with familial hyperparathy-
roidism syndromes, which corresponds to about 10% 
of all cases (3) (C-4). Parathyroid carcinoma rarely oc-
curs and is responsible for only 0.7% of all cases (2) 
(C-4) (Table 2).
Diagnosis and management of primary hyperparathyroidism 
Table 2. Causes of primary hyperparathyroidism
Pathological conditions related to familial/isolated PHPT*
Single adenomas (85%)
Hyperplasia and multiple adenomas (15%)
Carcinomas (0.5%)
Clinical conditions associated to familial PHPT*
MEN** type 1 and 2 
Hyperparathyroidism-jaw tumor syndrome
Familial isolated hyperparathyroidism
* Primary hyperparathyroidism; ** Multiple endocrine neoplasia.
Familial primary hyperparathyroidism relates to va-
rious pathological entities, including multiple endo-
crine neoplasia type 1 (MEN 1) and type 2 (MEN 2), 
hyperparathyroidism-jaw tumor syndrome, and isolated 
familial hyperparathyroidism (7) (Table 2).
Despite MEN1 being a rare cause of PHPT, occur-
ring in 2%-4% of cases, PHPT is the most common en-
docrine disorder in this disease, being present in virtually 
100% of patients older than 50 years, and being the first 
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sign of the multiglandular syndrome in most patients 
between 20 and 30 years (8). Therefore, the diagnosis 
of PHPT in young adults should stimulate a search for 
MEN1, including their first-degree relatives (7) (D).
The prevalence of PHPT in MEN2A is lower than 
in MEN1, occurring in 20%-30% of cases. In addition, 
most patients with PHPT present more discrete clinical 
features than those that occur in patients with MEN1 
(9) (C-4).
Hyperparathyroidism-jaw tumor syndrome is a rare 
disease where jaw bone tumors associated with PHPT 
are found. Parathyroid cancer has been diagnosed in 
more than 15% of the cases (9) (C-4).
In isolated familial hyperparathyroidism, close rela-
tives are diagnosed in the absence of other endocrinop-
athies. This familial variant of PHPT may correspond 
to a phenotype of syndromes such as subclinical MEN1 
and MEN2 (8).
Severe neonatal hyperparathyroidism is a rare con-
dition in which newborns have severe hypercalcemia 
associated with high levels of PTH, muscle hypotonia 
and respiratory distress. It usually occurs due to the 
presence of homozygous inactivating mutation of cal-
cium sensing receptor gene (10).
Some situations that may explain the appearance of 
PHPT, such as irradiation or rare genetic abnormali-
ties, can be identified in a small percentage of patients 
(11-14) (C-4). A cohort study conducted with workers 
at the Chernobyl nuclear plant in 1986, demonstrated 
that subsequent PHPT developed in 15 of the 61 in-
dividuals (OR 63.4, 95% CI 35.7-112.5). The average 
radiation dose received was 0.3 to 8.7 Gy (13) (B-2B).
PHPT has also been reported in patients receiving 
radiation in benign situations. A study of 2,555 pa-
tients receiving doses as low as 0.5 Gy before the age 
of 16, followed for 50 years, showed a dose-dependent 
increased risk of PHPT (14) (B-2B). When patients 
with sporadic PHPT (389 patients) were compared to 
patients with a history of irradiation (49 patients), in 
a retrospective study, no difference in the clinical pre-
sentation, pathology or recurrence was observed over 
a 6-year follow-up period (15) (B-3B). However, ex-
posed patients may have concomitant thyroid nodules 
which can also be related to intrathyroid parathyroid 
lesions (16) (B-3B).
In relation to radioiodine therapy, the incidence of 
PHPT was not increased significantly in a prospective 
study of 125 patients with thyrotoxicosis treated with 
I131, after a 21-year follow-up (17) (C-4).
Abnormalities in growth factor genes, proto-onco-
genes or tumor suppressor genes have been associated 
with the development of parathyroid tumors. Among 
the genes involved are the PRAD1/cyclin D1 gene for 
sporadic tumors (18-21) (C-4), RET for familial tumors 
(22,23) (C-4), and MEN1(24,25) (C-4) and HRPT 
(13,14) (C-4) for both sporadic and familial tumors.
The vitamin D receptor gene (VDR) may play a role 
in controlling the appearance of parathyroid adenomas, 
possibly due to the actions of 1,25-dihydroxyvitamin 
D to inhibit parathyroid cell proliferation in culture 
medium. While of interest, and presenting a plausible 
etiology, VDR gene inactivation does not seem to have 
a primary role in parathyroid gland tumorigenesis (26). 
However, vitamin D deficiency can alter the phenotypic 
expression of parathyroid tumors (27) (C-4).
Some small studies have also shown that defects in 
the Wnt/β-Catenin signaling pathway are associated 
with the appearance of PHPT (28,29) (C-4), but these 
findings need validation in larger studies.
DIAGNoSIS oF PRImARY 
HYPeRPARATHYRoIDISm 
Excessive secretion of PTH from one or more para-
thyroid glands causes hypercalcemia and constitutes 
the biochemical hallmark of PHPT (30). The finding 
of reproducible hypercalcemia in routine biochemical 
tests is a clue to the diagnosis of PHPT, especially in in-
dividuals over 50 years old and in postmenopausal wo-
men (31). About 40% of serum calcium is bound to al-
bumin and serum levels, thus, should be adjusted using 
the formula: corrected calcium = serum calcium found 
in mg/dL + [0.8 × (4-serum albumin)]. The measu-
rement of ionized calcium could be useful in selected 
cases such as in patients with hyper- or hypoalbumine-
mia, thrombocytosis, Waldenström macroglobulinemia 
and myeloma. In the latter two instances, hypercalce-
mia may be present but the ionized serum calcium is 
normal (artifactual hypercalcemia) (32,33) (C-4).
A cohort study based on the population of Tayside 
used the following biochemical criteria for diagnosing 
PHPT: 1) albumin-corrected serum calcium > 10.22 
mg/dL (reference values : 8.4-10.22 mg/dL) at least 
on 2 occasions, with serum PTH > 13.5 ng/L (refer-
ence values : 4.5-31.05 ng/L); or 2) albumin-corrected 
serum calcium > 10.22 mg/dL on only one occasion 
with serum PTH > 31.05 ng/L (34). These values of 
serum PTH correspond to 20 pg/mL for assays with 
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reference range between 10 to 65 pg/mL (34) (B-2B). 
Although not all patients selected by these criteria and 
who have serum PTH levels within the reference range 
have morphological confirmation, it seems reasonable 
to consider inappropriately normal serum PTH levels, 
in the presence of hypercalcemia, as indicative of the 
diagnosis of PHPT. 
The causes of secondary hyperparathyroidism such 
as the use of thiazide diuretics (35) (C-4) and lithium, 
vitamin D deficiency, bisphosphonates, and renal fail-
ure, should be excluded (36). Tertiary hyperparathy-
roidism in renal failure, in addition to genetic causes 
such as familial hypocalciuric hypercalcemia also need 
to be excluded. The differential diagnosis with condi-
tions that lead to hypercalcemia should be considered. 
The finding of a normal corrected serum calcium asso-
ciated with elevated serum PTH in the absence of other 
causes help to establish the diagnosis of normocalcemic 
PHPT (see details below).
Even in the presence of glomerular filtration rates 
between 40-60 mL/min, the serum PTH levels may be 
elevated without being associated with PHPT. Hyper-
calcemia with very low or undetectable plasma PTH le-
vels is present in malignant diseases in which case PTHrP 
is often responsible for serum calcium elevation (33,37).
In regard to assays for detection of elevated PTH 
levels, the second generation ones (measure of intact 
PTH or “total”) measure both the 1-84 primary amino 
acid sequence of PTH (considered the biologically ac-
tive full-length moiety), and other large fragments with 
uncertain biological activity, for example, the truncated 
PTH (7-84), which besides being found in PHPT, can 
also be detected in normal persons and accumulate in 
patients with renal failure (38) (C-4). A so-called third 
generation or biointact assay that measures only the 
full length molecule PTH (1-84) was developed to 
help solve this problem. However, there are few stu-
dies comparing the diagnostic sensitivity between the 
second and third generation assays, some showing the 
superiority of third generation assays compared to the 
second (39) and others not (40-42).
Laboratory evaluation should include renal function 
tests and serum measurement of 25OHD. The 24-hour 
urinary calcium and the serum creatinine level should 
be measured. The calcium clearance/creatinine clear-
ance ratio less than 0.01 suggest, but does not prove, 
familial hypocalciuric hypercalcemia (22,32) (C-4).
Serum phosphorus levels are usually found to be 
low in severe disease, and low-normal in milder forms 
(42). Specific markers of bone formation (osteocalcin, 
bone-specific alkaline phosphatase) or bone resorption 
(deoxypyridinoline, N-telopeptide and C-telopeptide) 
tend to be in the normal-high range or slightly above 
the reference values (1).
Most subjects who present with PHPT are asymp-
tomatic. Reports of overt skeletal involvement with os-
teitis fibrosa cystica ranges from negligible to as high as 
30%. Nephrolithiasis occurs in about 20% of patients and 
a neuropsychiatric or neurocognitive component, not 
necessarily directly linked to PHPT, has been reported 
in much smaller percentage, about 2%-3% (43) (C-4).
A renal ultrasound should be performed if history 
suggests nephrolithiasis, and can be considered even 
in the absence of these symptoms to rule out nephro-
calcinosis or nephrolithiasis, findings that would argue 
for surgical intervention (44-46) (B-3B). Bone mineral 
density (BMD) of the lumbar spine, femur and distal 
1/3 radius by dual energy X-ray absorptiometry (DXA) 
should be evaluated in all patients with PHPT because 
continuously high PTH exposure has a catabolic effect, 
mainly at cortical bone (i.e., the distal third radius). 
Most have involvement of cortical bone with apparent 
preservation of the trabecular bone by DXA. It is not 
uncommon to detect skeletal involvement by DXA (os-
teopenia or osteoporosis) in subjects who do not have 
radiological features of PHPT (47,48) (B-3B).
THe SKeLeTAL mANIFeSTATIoNS oF PRImARY 
HYPeRPARATHYRoIDISm
After the 1970s, when the routine use of serum cal-
cium, as part of a biochemical screening profile, had 
become common practice, the diagnosis of PHPT 
on biochemical grounds, increased markedly without 
evidence for overt skeletal manifestations (49) (C-4). 
Even at this early stage of the disease, however, asymp-
tomatic PHPT can be associated with high bone tur-
nover (50,51) (C-4), a reduction in BMD (52) (B-
2B) and increased fracture risk (53,55) (B-2B). After 
successful parathyroid surgery increased bone remo-
delling subsides (51,55) (C-4), BMD increases (55-57) 
(B-2B) and, with limited data, fracture risk falls (58) 
(C-4). The amelioration of preoperative findings after 
parathyroid surgery suggests that the hyperparathyroid 
state is directly responsible for them. 
The prevalence of PHPT and its impact on BMD 
were evaluated in 3,014 men aged between 69 and 81 
years in the Swedish cohort of the MrOs study. Indi-
Diagnosis and management of primary hyperparathyroidism 
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viduals with a low glomerular filtration rate (< 21 mL/
min/1.73 m2) and vitamin D deficiency (< 50 nmol/L) 
were excluded. BMD was compared between patients 
with and without PHPT. The prevalence of PHPT was 
estimated at 0.73%. BMD at the total hip and femoral 
neck was lower in the PHPT group than in the con-
trol group. Individuals with inappropriately high intact 
PTH levels were compared to the rest of the cohort. In 
that subgroup BMD at the total hip and lumbar spine 
was lower (p < 0.05) (52) (B-2B). Another subgroup 
from Mr. Os gave similar results (59). 
In a controlled clinical trial, patients with mild 
PHPT were randomized to parathyroidectomy (PTx) 
(n = 25) versus non-PTx (n = 28). After 24 months of 
follow-up, a significant increase in BMD at the femo-
ral neck and total hip was seen, but not at the lumbar 
spine or forearm in patients undergoing PTx compared 
with non-PTx patients. There was also a decrease in 
bone-specific alkaline phosphatise activity after PTx 
(57) (B-2B). Another study of patients followed for 5 
years after PTx, showed a significant increase in lumbar 
spine BMD, but not hip or distal third of the radius 
compared to baseline and a decrease in bone turnover 
markers (55) (C-4).
 A case-control study evaluated the rate of verte-
bral fractures in 150 postmenopausal women with spo-
radic PHPT and 300 healthy matched controls (53). 
Vertebral fractures were detected in 24.6% of patients 
with PHPT and 4.0% of controls (P < 0.0001). Most 
vertebral fractures were mild. To identify if risk fac-
tors related to vertebral fractures among patients with 
PHPT differed from those of control, a logistic regres-
sion analysis was performed with variables of age, age at 
menopause, years since menopause, body mass index, 
serum total calcium, PTH, 25(OH) vitamin D, BMD 
at the lumbar spine and femoral neck. There was an as-
sociation of vertebral fractures with BMD at the lumbar 
spine in patients with PHPT (P = 0.002) and controls 
(P = 0.004) and with age (P = 0.04) in controls. To 
examine whether PHPT conveyed an additional risk 
of vertebral fracture, a logistic regression analysis was 
performed on the entire sample (patients and controls) 
using the PHPT status as covariate. Age (P = 0.015) 
and lumbar spine BMD (P = 0.01) remained associ-
ated with vertebral fractures, with a strong correlation 
of BMD at the lumbar spine and PHPT (P < 0.0001) 
(53) (B-3B).
A retrospective cohort study evaluated fracture-
free survival at 10 years in 533 patients with PHPT. 
The initial mean calcium, PTH and serum creatinine 
were 11.1 mg/dL, 116 pg/mL and 0.9 mg/dL, re-
spectively. PTx was performed in 30% of patients and 
70% were observed. Fracture-free survival at 10 years 
after PHPT diagnosis was 94% in the PTx group and 
81% in the observation group (p = 0.006). Compared 
with observation, PTx improved fracture-free survival 
at 10 years by 9.1% (p = 0.99), 12% (p = 0.92) and 
12% (p = 0.02) in patients with T-score ≥ -1.0, T-score 
between -1.0 and -2.5, and T-score < -2.5, respectively. 
In multivariate analysis, PTx was independently associ-
ated with decreased fracture risk (HR = 0.41, 95% CI 
0.18-0.93), while non-black patients (HR = 2.94, 95% 
CI 1.04-8.30) and T-score < -2.5 (HR = 2.29, 95% 
CI 1.08-4.88) remained independently associated with 
increased fracture risk (58) (C-4).
Studies evaluating different skeleton sites through 
different methods (three-dimensional analysis of 
bone biopsy using micro-computerized tomography, 
conventional two-dimensional bone histomorphom-
etry and quantitative electron imaging) showed differ-
ences in the effects of PHPT on the trabecular bone 
(33,51,60,61).
Conventional two-dimensional bone histomor-
phometry in patients with PHPT showed thinning 
and increased cortical porosity, endosteal resorption, 
and preservation of trabecular bone volume and con-
nectivity (60) (D-5). An analysis of three-dimensional 
transiliac bone biopsy, using micro-tomography in 29 
women with PHPT compared to 20 controls and in 
15 men with PHPT, concluded that trabecular bone 
microarchitecture is preserved in patients with mild 
PHPT (61) (C-4).
In contrast, a cross-sectional study comparing 36 
women with PHPT with 100 healthy controls, quan-
titative tomography of the radius showed a significant 
20% reduction in volumetric BMD in trabecular bone 
and a significant reduction of 5% in the cortical region 
of interest (51). In this same group, BMD by DXA 
densitometry was similar at the lumbar spine, but de-
creased in the distal third of the radius compared with 
the controls.
In another study comparing 52 women with PHPT 
(normocalcemic and hypercalcemic) with 56 controls, 
peripheral quantitative computed tomography of the 
tibia showed differences in both trabecular and cortical 
volumetric BMD, consistent with a catabolic effect on 
both types of bone in patients with hypercalcemic and 
normocalcemic PHPT (62) (C-4).
Diagnosis and management of primary hyperparathyroidism 
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However, a cohort study of 116 patients with PHPT 
(85% asymptomatic) followed for 15 years showed that 
PTx is associated with improved BMD in cortical and 
trabecular skeletal sites. This study aimed to evaluate 
BMD during 15 years in patients undergoing or not 
undergoing PTx. BMD was measured at the lumbar 
spine, femoral neck and distal radius. In patients who 
underwent PTx, there was a significant increase in BMD 
at the 3 sites after 15 years of follow up compared to 
baseline. In the group not subjected to PTx, BMD did 
not change in the 3 sites for 8 years and remained stable 
in the lumbar spine after 15 years of follow up, but 59% 
of patients had a 10% decrease in BMD at one or more 
locations during the 15 year period (56) (B-2B).
NeuRoPSYCHIATRIC mANIFeSTATIoNS
Psychiatric symptoms may occur in up to 23% of pa-
tients with PHPT, of which 78% have depression and 
anxiety (63). Other manifestations found are fatigue, 
memory loss, difficulty concentrating, irritability, soma-
tization, mood and sleep disorders (49,64-66) (C-4).
The prevalence of these abnormalities is not well 
defined due to the lack of rigorous evaluation of these 
symptoms in most studies, a small number of studies, 
and wide variation in the instruments used to assess the 
psycho-cognitive manifestations (66).
A case-control study that compared 39 postmeno-
pausal patients with mild PHPT with 89 controls 
showed a higher prevalence of depression and anxiety, 
in addition to worse performances on tests of verbal 
and nonverbal memory in women with PHPT (67). In 
this study, after PTx, there was significant improvement 
in depressive symptoms, non-verbal abstraction and 
some aspects of verbal memory (B-3B).
Three randomized clinical studies were conducted 
to evaluate the effect of PTx versus conservative treat-
ment in patients with mild PHPT on neurocognitive 
symptoms, among other manifestations (57,68,69) 
(see details in the “Effects of Parathyroidectomy” sec-
tion). The data from these studies suggest a significant 
difference in favor of surgical treatment (A-1A). Fur-
thermore, the association of peripheral neurological 
disorders, especially sensory-motor polyneuropathy 
and PHPT, has been suggested by some (Table 3) (70-
76) (C-4).
Some studies have shown that there may be an im-
provement in neuromuscular symptoms after surgical 
cure (70-74,77). In a case-control study that evalu-
ated 9 patients with PHPT and neuromuscular disor-
ders, there was improvement in strength and fine mo-
tor movement four weeks after PTx in all patients with 
PHPT, which did not occur in the control group who 
underwent surgical treatment for benign thyroid disea-
se (77) (B-3B). Future research is clearly needed to 
better understanding of central and peripheral nervous 
system involvement in PHPT (78).
CARDIoVASCuLAR mANIFeSTATIoNS
Some studies have shown variable prevalence rates of 
cardiovascular abnormalities in patients with PHPT 
with variable degree of increased morbidity (79) and 
mortality as well (80-82) (C-4). These include arterial 
hypertension (83-85) (C-4), left ventricular hyper-
trophy (86-88) (C-4), cardiac function abnormality 
(86,89) (C-4), coronary artery disease (90) (C-4), vas-
cular abnormalities (91-94) (C-4), conduction distur-
bances (95) (C-4) and valvular and myocardial calcifi-
cation (96) (C-4). Lipid abnormalities with a decrease 
Table 3. Case reports of peripheral neuropathy related to primary hyperparathyroidism
Author Gender Age (years)
other cause of 
neuropathy Type of neuropathy
Histopathological 
findings
Resolution after 
parathyroidectomy
Conri and cols. (70) F1 34 Hypoglycemia Motor polyneuropathy Muscle atrophy, 
nonspecific acute axonal 
injury
Yes
Moskal (72) M2 63 Neoplasia Sensorimotor 
polyneuropathy
NR3 NR3
Logullo and cols. (73) M2 71 No Sensorimotor 
polyneuropathy
NR3 Yes
Olukoga (74) F1 65 No Sensorimotor 
polyneuropathy
NR3 Yes
Eufrazino and cols. (71) F1/M2 51/76 No Sensory polyneuropathy NR3 Yes
1 F: female; 2 M: male; 3 NR: not reported.
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in serum HDL-C and increase in triglycerides have also 
being described (79,97) (C-4).
There are few controlled studies on arterial hyper-
tension and PHPT, which is the reason why it is unclear 
whether left ventricular hypertrophy and diastolic dys-
function, when present, are secondary effects of hyper-
tension or directly caused by PTH and elevated serum 
calcium (91,98). The presence of PHPT was a stronger 
positive predictor of a higher rate of arterial resistance 
than age, sex, smoking, dyslipidemia, hypertension 
and diabetes mellitus, according to a study conducted 
at Columbia University, NY. The pulse wave analysis 
showed a higher rate of arterial resistance in patients 
with PHPT (28 ± 10 vs. 25 ± 10%) but without sta-
tistical significance (91) (C-4). Another case-control 
study evaluated left ventricular (LV) size, diastolic dys-
function and valvular calcification in patients with mild 
PHPT. After adjustment for potential confounders, no 
association between high levels of PTH, serum calcium 
or vitamin D deficiency with left ventricular hypertro-
phy or myocardial and mitral annular calcification was 
observed. These manifestations were present only in 
the more severe forms of the disease, or in the presence 
of arterial hypertension and other risk factors (99) (B-
3B). Data on the effects of PTx on those outcomes are 
still conflicting (85,100,101) (C-4).
Although the published literature about cardiovas-
cular consequences of PHPT is conflicting due to small 
sample size and/or low statistical power of most stu-
dies, more recent population studies have suggested 
that a milder form of the disease may be associated with 
increased all-cause mortality and an increase of fatal and 
nonfatal cardiovascular disease (65,102) (B-2B).
NoRmoCALCemIC PRImARY 
HYPeRPARATHYRoIDISm
Patients undergoing routine assessment or during an 
investigation of bone loss may present with increased 
serum PTH levels in the absence of hypercalcemia 
(49,103). The term normocalcemic primary hyperpa-
rathyroidism (NPHPT) was initially used in 1960 with 
a report of a group of patients with different characte-
ristics from those diagnosed with classic PHPT (104). 
The patients had normal serum calcium levels in the 
presence of high PTH levels (47,104) (B-2B). Nowa-
days, however, with the widespread availability of PTH 
assays and their use in the work up in individuals who 
are referred for syndromes of low bone mass, the con-
dition has gained increased attention by the scientific 
community (105).
In order to establish, with reasonable certainty, the 
diagnosis of NPHPT, it is mandatory to search for 
causes of secondary hyperparathyroidism (Table 4), 
particularly vitamin D deficiency (36,106) (B-2B). 
Table 4. Causes of secondary hyperparathyroidism
Chronic kidney disease (GFR* < 60 ml/min)
Medications (bisphosphonates, anticonvulsants, hydrochlorothiazide**, 
denosumab, furosemide, phosphorus)
Renal hypercalciuria
Malabsorption syndrome (celiac disease, cystic fibrosis)
25-OH vitamin D deficiency (< 50 nmol/L or 20 ng/mL)
Pseudohypoparathyroidism type 1
* GRF: glomerular filtration rate; ** Ref.: 106.
It remains uncertain whether NPHPT represents an 
incipient form of classic PHPT or a different spectrum 
of this condition (47). Follow-up should include peri-
odic measurement of the, serum calcium concentration 
(105,106) (B-2B).
If NPHPT is an incipient form of classic PHPT with 
hypercalcemia, the serum calcium would be expected 
to increase over time. A prospective study involving 
41 patients showed that approximately 20% of patients 
developed hypercalcemia over a 3-year period. In ad-
dition, 40% of normocalcemic patients showed disease 
progression by nephrolithiasis, hypercalciuria, bone 
loss and fractures, even though the serum calcium did 
not necessary increase. PTx showed clear-cut evidence 
for parathyroid disease (104) (C-4). 
It is important to note that the cohorts of NPHPT 
that have been described so far have come from refer-
ral centers. As such, these individuals often demon-
strate evidence for skeletal disease. It remains to be 
seen whether a different phenotype of NPHPT, as well 
as normocalcemic or subclinical hypoparathyroidism, 
would be discovered if community dwelling subjects, 
without referral bias, were to be screened (59,107).
Some other studies have also suggested that NPHPT 
is not an indolent condition. A retrospective case series 
study compared the clinical and laboratory data of pa-
tients with mild hypercalcemic PHPT (n = 37) with pa-
tients with NPHPT (n = 33). The frequency of nephro-
lithiasis was similar between the two groups (18.9% vs. 
18.2%, p = 0.937) (46). This was also observed when 
NPHPT patients were compared with non-PHPT con-
trols (47) (C-4).
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ImAGING PRoCeDuReS AND LoCALIZATIoN 
TeCHNIQueS 
Ultrasonography of the anterior neck is widely used to 
locate the parathyroid lesion. While inexpensive and 
non-invasive, it has the disadvantages of limited re-
solving power and being operator-dependent (108). 
Moreover, with ectopically located parathyroid glands, 
particularly intrathyroidal parathyroid adenoma, it can 
be difficult to differentiate them from thyroid nodu-
les (Table 5). Ultrasonography has a sensitivity of 88% 
and specificity of 94% but when combined with Tc-
-99m Sestamibi scan by SPECT-CT, the sensitivity and 
specificity may rise to 97 and 100%, respectively (109) 
(C-4). 
minimally invasive parathyroidectomy (MIP), which 
can be performed as a same-day procedure, reducing 
patient morbidity and costs (112) (C-4).
A study performed in our institution showed that 
Sestamibi imaging may also detect brown tumors in se-
vere PHPT (113). This abnormal uptake is still not well 
explained, but seems to be due to increased osteoclas-
tic activity and perfusion of the lesion. In the presence 
of metastatic disease the differential diagnosis between 
benign and malignant disease can be difficult (113).
Sestamibi scanning may show false-positive results in 
the presence of thyroid nodules and false negatives, due 
to the size and location of the affected parathyroid lesion. 
In this situation, fine needle aspiration and measurement 
of PTH in the aspirated fluid may indicated (114). A 
comparative study between a group of 15 women with 
PHPT and 15 women without PHPT who had nodules 
visualized by ultrasound, found very high PTH values 
with a mean of 4,919 pg/mL in PHPT patients com-
pared to 10.65 pg/mL in controls (114) (C-4).
INDICATIoNS FoR PARATHYRoIDeCTomY
PTx is the treatment of choice for all patients with 
symptomatic PHPT. Various studies (115,116) have de-
monstrated regression of skeletal abnormalities such as 
an increase in BMD and in severe cases, reduction of 
osteoclastomas (C-4). Biochemical aspects of the disea-
se return to normal promptly. According to the Third 
International Workshop, surgery should also be recom-
mended for asymptomatic patients, if a criterion for 
surgery is met (78). In asymptomatic PHPT, surgery is 
recommended if patients meet one or more of the follo-
wing criteria: (Table 6) (D): 1. T-score < -2.5 at any site 
(lumbar spine, hip, or distal 1/3 forearm) or history of 
fragility fracture (68); 2. Age < 50; 3. Creatinine clearan-
ce < 60 mL/min/1.73 m2; 4. Serum calcium concentra-
tion > 1 mg/dL above the laboratory reference value. 
Ideally, this criterion should be met by measurement of 
3 albumin-corrected calcium values in the fasting state. 
Any drugs that could theoretically interfere with the cal-
cium measurement (i.e., lithium or thiazide diuretics) 
should be stopped at least 4-6 weeks in advance (117).
The workshop also pointed out that parathyroid 
surgery in asymptomatic patients who do not meet sur-
gical guidelines is not an inappropriate course if there is 
consensus among the endocrinologist, the parathyroid 
surgeon and the patient, and there are no medical con-
traindications to parathyroid surgery. 
Table 5. Parathyroid localization techniques
Cervical ultrasonography
Computed tomography
Magnetic resonance imaging
Tc-99m sestamibi scintigraphy 
PTH measurement in nodule aspiration fluid (FNA*)
* FNA: fine needle aspiration.
Diagnosis and management of primary hyperparathyroidism 
Tc-99m uptake in the sestamibi scan depends on the 
size and weight of parathyroid lesion. In a study of 64 
patients with various degrees of severity of PHPT, Tc-
99m Sestamibi showed positive results in 64% of pa-
tients with asymptomatic PHPT, 83% in the group with 
nephrolithiasis without bone involvement and 100% in 
those with severe disease characterized by osteitis fibro-
sa cystica; of those, 70% showed increased uptake on the 
initial images, whereas in the other groups, increased 
uptake was seen only on the delayed images (110) (C-4). 
In a prospective cohort study with 487 patients, the 
positive Sestamibi scan was associated with higher rates 
of biochemical cure than those with a negative test (97% 
vs. 89%, respectively; p = 0.008) (111) (B-2B). 
The four-dimensional computed tomography per-
mits locating abnormal parathyroid tissue (adenoma-
tous or hyperplastic) with high accuracy as compared to 
ultrasonographic and scintigraphic techniques. In a ret-
rospective study of 35 cases of histologically confirmed 
PHPT, 4D-CT demonstrated a sensitivity of 91% (32 
positive cases). The method successfully located a 
single affected gland with 93% accuracy. In the assess-
ment of multiglandular disease, however, sensitivity fell 
to 44% but specificity was impressively, at 100% (112). 
Preoperative localization of abnormal parathyroid tis-
sue permits less aggressive surgical techniques such as 
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3.4%, respectively. Recurrent laryngeal nerve injury was 
seen in 0.2% of cases, postoperative bleeding in 0.8% 
and transient hypocalcemia in 1.8%. There was no ex-
cess mortality. The mean operative time was 52.5 ± 
30.2 minutes (108) (C-4).
Recent techniques, including improved preopera-
tive localization techniques, with or without intraop-
erative PTH measurement, endoscopic refinement and 
intraoperative gamma probe use have all resulted in the 
widespread application of minimally invasive surgery 
(122).
MIP encompasses a number of different techniques 
such as: open approaches (open minimally-invasive 
parathyroidectomy – OMIP) (123), minimally-inva-
sive radio-guided parathyroidectomy (MI-RP) (124), 
video-assisted parathyroidectomy (MIVAP) (125,126), 
and purely endoscopic parathyroidectomy (EP) (127).
A prospective, randomized study of 60 individuals 
with concordant localization of a parathyroid adenoma 
by ultrasonography and technetium-99m sestamibi 
scintigraphy, who were eligible for MIP, were random-
ized into two groups: MIVAP and OMIP. Patients 
undergoing MIVAP vs. OMIP had similar operative 
time (P = 0.22) and rates of transient hypocalcemia (P 
= 1.0); less pain 4, 8, 12, and 24 hours after surgery 
(P < 0.001), less analgesia requirement (P = 0.01), bet-
ter physical functioning and quality of life in the early 
postoperative period (P = 0.02 and P = 0.003, respec-
tively). Shorter scar length (P < 0.001) and greater aes-
thetic satisfaction were observed 1 month after surgery 
(P = 0.006), but there were no significant differences 
6 months post-surgery. MIVAP was more expensive 
(P < 0.001), while the average hospital stay was simi-
lar (P = 0.22). Differences between serum calcium and 
PTH during 6 months of follow-up were not signifi-
cant (126) (B-2B).
There is also some evidence that MIVAP has some 
advantages over other purely endoscopic procedures 
and video-assisted parathyroidectomy through a lateral 
approach (VAP-LA), in terms of bilateral exploration 
and associated procedures on the thyroid gland (128) 
(C-4).
There are few prospective, well-designed studies, 
comparing conventional PTx and minimally invasive 
exploration despite showing no differences in cure or 
complication rates when performed by experienced 
surgeons (129-131) (B-2B). There may be differ-
ences when operative time and costs are considered 
(129,132,133) (A-1B).
Table 6. Indications for surgery in asymptomatic primary hyperparathy-
roidism treatment according to the NIH Third International Workshop
1 – Serum calcium > 1 mg/dL above ULN*
2 – Creatinine clearance < 60 mL/min/1.73 m²
3 – T-score < -2.5 at the lumbar spine, hip and/or distal radius or previous 
fragility fracture
4 – Age < 50 years
5 – Patients whose medical monitoring is not possible
* ULN: upper limit of normal. Adapted from Ref. 78.
Considering the minimal significant changes in the 
rate of bone loss during the natural evolution of the 
disease (78,118), other asymptomatic PHPT patients 
who do not meet criteria for surgery or who have a 
contraindication, should be followed with regular 
BMD monitoring. Patients with vitamin D deficiency 
(serum 25-OHD < 20 ng/mL) should receive ade-
quate replacement, following the recommendations for 
patients without PHPT (78). 
Randomized studies (57,68,69), but with limited 
follow-up time (1-3 years) have demonstrated benefits 
in quality of life and BMD in asymptomatic patients 
who undergo surgery (A-1B). 
These guidelines from the Third International 
Workshop are not rules. The decision for or against 
parathyroid surgery should be made individually, based 
upon each affected patient, the physician’s judgement, 
and the experience and availability of an experienced 
parathyroid surgeon.
Cure rates with resection of the affected glands are 
95% to 98% in the hands of experienced parathyroid sur-
geons. Complications such as bleeding, postoperative 
hypocalcemia and recurrent laryngeal nerve injury are 
very unusual (1%-3%). The MIP technique may be as-
sociated with lower morbidity and costs (119) (B-3B).
SuRGICAL PRoCeDuReS
The surgeon’s experience, in large part, determines 
cure and complication rates of PTx (C-4) (120,121). 
Neck exploration with direct visualization and identi-
fication of all abnormal parathyroid glands, with their 
subsequent removal, is the gold standard in the surgical 
treatment of PHPT (30).
 A retrospective study of 1,112 patients, over a pe-
riod of 17 years, evaluated the cure rate, complications 
and operative time of PTx with bilateral neck explora-
tion. The cure and complication rates were 97.4% and 
Diagnosis and management of primary hyperparathyroidism 
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A prospective randomized study compared MIP to 
conventional PTx in 48 patients with PHPT. In the 
group with bilateral neck exploration, neither preop-
erative imaging nor intraoperative PTH measurements 
were performed. Patients in both groups had similar 
cure rates and operative times. In the group undergo-
ing MIP there was less pain 4, 8, 16, 24, 36 and 48 
hours postoperatively (p < 0.001), lower analgesic con-
sumption (p < 0001), lower analgesia requirement (p < 
0.001), less scarring (p < 0.001) and greater aesthetic 
satisfaction 2 days, 1 month (p < 0.01) and 6 months 
after surgery (< 0.05), but after 1 year the aesthetic sat-
isfaction became non-significant (p = 0.38). MIP was 
more costly and there was no difference in the quality 
of life in both groups 1 month and 6 months after sur-
gery (133) (A-1B) (Table 7). 
a small case-control study, an 8% increase in cortical bone 
thickness and area was observed, in addition to an incre-
ase in volumetric BMD, 1 year after PTx (136) (B-3B).
Some randomized clinical trials have demonstra-
ted an increase in BMD after PTx (68,69,137) (Table 
8). In one study, after 2 years of surgical treatment, 
there was a significant increase in lumbar spine BMD 
in the surgically treated group, when compared with 
conservative treatment, in which BMD remained un-
changed (1.01 ± 0.18 vs. 1.13 ± 0.19, p < 0.01) (68) 
(A-1B). Another randomized study showed that after 2 
years of surgery, modest improvement in femoral neck 
bone density (a difference between the groups of 0.8% 
per year, P = 0.01) and total hip (difference between 
groups of 1.0% per year, P = 0.001) in the group that 
underwent PTx, compared to the conservative treat-
ment group (57) (A-2B).
Observational studies have also demonstrated signifi-
cant improvement in BMD after PTx (114,135,138,139). 
In a prospective cohort of 121 patients with PHPT fol-
lowed for 10 years, there was an increase of 12% to 15% 
in BMD of patients undergoing PTx (135), especially in 
the lumbar spine and hip (B-2B).
In a 15 year follow-up of the same cohort that did 
not undergo PTx, there was a 10% decrease in cortical 
bone in the femoral neck and 35% in the distal radius 
(56) (B-2B). Most of the bone loss occurred after the 
first 8 years of follow-up. Most studies (135,138-143), 
but not all (143,144) do not show reduction in BMD 
at any sites during the first years of observation without 
intervention (B-2B).
Fracture risk
Despite a small study suggesting that mild PHPT does 
not increase the risk of vertebral fracture (145) (B-
2B), observational cohort and case-control studies 
suggest that there may be an increased risk of verte-
bral and nonvertebral fractures (53,54,146,147) (B-
2B). There are no data available yet from randomi-
zed clinical studies evaluating fracture risk reduction 
after PTxs. However, observational studies suggest 
a benefit for the group that underwent intervention 
(146,147) (B-2B).
Neuropsychiatric symptoms
In some situations, PTx appears to improve some neu-
ropsychiatric parameters, such as cognition, mood, an-
xiety (148,149) (C-4), quality of life and psychological 
function (57,68) (B-2B).
Table 7. Advantages of minimally invasive parathyroidectomy
1 – Less postoperative pain
2 – Less requirement for analgesia 
3 – Lower consumption of analgesics
4 – Less scarring
5 – Greater cosmetic satisfaction
Diagnosis and management of primary hyperparathyroidism 
Another randomized, prospective study on 45 
patients who underwent conventional PTx or MIP, 
showed similar cure rates for both procedures within 6 
months of follow-up. The operative time was 22 min-
utes shorter in patients undergoing MIP and serum 
calcium levels were slightly lower in the first 4 postop-
erative days in the group that underwent bilateral neck 
exploration (129) (B-2B).
BeNeFITS oF PARATHYRoIDeCTomY
PTx is a definitive therapy for PHPT which may pro-
vide, in addition to biochemical cure, reduced risk of 
nephrolithiasis, improved BMD, decreased risk of frac-
tures and improved quality of life (134).
Bone mineral density
Asymptomatic patients undergoing surgery have an in-
crease in BMD that is > 10% during the first decade (135) 
(B-2B). Symptomatic patients with severe bone invol-
vement may have greater increases of as much as 60 to 
100% in the first post-operative year (2) (B-3B). After 15 
years of PTx, the gain in BMD remains stable in the lum-
bar spine, femoral neck and distal radius (56) (B-2B). In 
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Table 8. Results of randomized trials on the effects 1 year after PTx on BMD and neuropsychiatric symptoms in patients with PHPT
N (PTx)
-
sCA (mg/dL)
P
-
sPTH (pg/mL)
P
-
BmD (g/cm2)
P
-
SF-36
P
-Before PTx After PTx Before PTx After PTx observation x PTx observation x 
PTx
Rao and 
cols. (57)
25 10.41 ± 0.5 9.33 ± 0.42 < 0.001 87 ± 27 39  ± 28  < 0.001 ↑ 1.2% (spine)
↑ 0.4% (femur)
↑ 0.4% (forearm)
< 0.001
0.03 < 0.001
Improvement in 
social 
functioning
Improvement in 
emotional 
functioning
< 0.007
< 0.012
Ambrogini 
and cols. 
(69)
24 NR NR NR NR NR NR ↑ 6.5% (trochanter)
↑ 5.3% (spine) 
↑ 4.5% (hip)
↑ 4.4% (femoral neck)
0.0001 
0.0002
0.0001
0.01
Improves pain
Improves 
general health
Improves vitality
Improves 
mental health
0.001
0.08
0.003
0.017
Bollerslev 
and cols. 
(68)
60 10.7 ± 0.32 9.9 ± 0.56 < 0.001 107.5 ± 58.3 44.9 ± 20.4 < 0.001 Observation
1.04 ± 0.20
PTx
1.13 ± 0.19
< 0.05 Improvement in 
social 
functioning
Improvement in 
emotional 
functioning 
< 0.05
< 0.05
PTx: parathyroidectomy; BMD: bone mineral density; PHPT: primary hyperparathyroidism; sCA: serum calcium; sPTH: serum parathyroid hormone; NR: not-related; SF-36: Quality Questionnaire 
“Short Form-36 Health Survey”.
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Most published studies are observational and, thus, 
have important limitations, such as selection bias, lack 
of uniform methods for description of neurological 
and psychiatric symptoms, presence of symptomatic 
patients with PHPT and inadequate control groups. 
Ideally, randomized long-term studies are needed to 
determine the actual benefit of PTx for such symptoms. 
However, one of the difficulties lies in the recruitment 
of asymptomatic patients who agree to undergo ran-
domization for surgical treatment (150,151).
Despite these limitations, some randomized stu dies 
have demonstrated a benefit of Ptx on neuropsychi-
atric symptoms in patients with asymptomatic PHPT 
(57,69,137) (Table 8).
In a study from Norway, 191 patients (mean cal-
cium, 10.8 mg/dL) were randomized to surgical or 
conservative groups (68). At baseline, all patients had 
low psychosocial (quality of life) and mental health 
rates, as assessed by questionnaires “Short Form-36 
Health Survey” (SF-36) and “Comprehensive Psycho-
pathological Rating Scale”, respectively. There were no 
significant improvements in these parameters in the sur-
gically treated group compared to the control group. 
There was only a small difference in physical and emo-
tional symptoms in the surgery group (68) (A-1B).
In another study, among 283 patients selected, 53 
agreed to participate in the randomization (mean se-
rum calcium 10.3 mg/dL) for conservative or surgical 
treatment. At baseline, the “Short Form-36 (SF-36) 
Health Survey” mean score was similar to the normal 
population. Those who underwent the conventional 
surgical treatment showed little change in psychosocial 
function after 2 years, despite a significant decline in 
the conservative group. After 42 months of follow-up, 
there was a significant benefit of surgery in 2 domains 
of the SF-36 scale (social functioning and emotional 
problems) (57) (A-1B).
Another study randomized 50 patients, with mean se-
rum calcium of 10.2 mg/dL, for surgical or conservative 
treatment. There were modest improvements in some 
quality of life parameters in SF-36 of patients undergo-
ing surgical treatment, among them, generalized pain, 
vitality, general health and mental health (69) (A-1B).
Cardiovascular risk
In some studies, Ptx has shown some benefit in cardio-
vascular parameters such as blood pressure, left ventri-
cular diastolic function and left ventricular mass index 
(152,153). Other studies, however, do not confirm 
these findings (100,150,154,155) (B-3B).
Some cohort studies demonstrate improved survival 
after PTx (146,152), which was not confirmed by a 
more recent study that provided long-term follow up 
(153) (B-2B).
Few randomized controlled trials have evaluated the 
cardiovascular benefits of surgical treatment in asymp-
tomatic PHPT. In a study on 116 patients, comparing 
conservative treatment versus PTx, the mean reduction 
in blood pressure did not differ significantly between 
groups, as well as the serum levels of adiponectin, lip-
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Table 9. Results of studies on the effects of PTx on blood pressure (BP) and left ventricular (LV) hypertrophy in patients with PHTP
N
(PTx)
sCA 
(mm/L)**
P
sPTH
P
Change BP 
(mmHg)
P
Changes in 
cardiac 
structure
(LVH)
P
Before PTx After PTx Before PTx After PTx
Persson and 
cols. (153)
Randomized
49 2.67 ± 0.06 2.4 < 0.01 11.08 ± 3.87
(pmol/L)
5.0 (pmol/L) < 0.01 No change NS Reduction of LV 
mass
NS
Farahnak and 
cols. (154)
Case control
51 2.62 ± 0.13 2.28 ± 0.08 < 0.001 122.6 ± 43.6 
(pg/mL)
48.8 ± 15.9
(pg/mL)
< 0.001 Decreased < 0.05 NS NS
Bollerslev and 
cols. (116)
Randomized
116 2.69 ± 0.11 2.4 < 0.01 10.1 ± 4.0
(pmol/L)
5.0
(pmol/L)
< 0.01 Decreased < 0.05 NR NR
Ishay and cols. 
(100)
Case control
34 11.2 ± 0.7* NR - 222.9 ± 189.8 
(pg/mL)
NR - Decreased 0.02 NR NR
* In mg/dl; ** in mmol/L; NR: not reported; NS: non-significant; PTx: parathyroidectomy; PHTP: primary hyperparathyroidism; sCA: serum calcium; sPTH: serum parathyroid hormone.
Diagnosis and management of primary hyperparathyroidism 
ids, leptin, C-reactive protein and markers of endothe-
lial dysfunction, such as von Willebrand factor (116) 
(B-3B).
In an observational study, surgical treatment was 
associated with improvement of left ventricular hyper-
trophy in patients without previous hypertension (89) 
(B-3B). However, most other observational studies in-
dicate that hypertension does not improve significantly 
after PTx and should not be considered an indication 
for surgical treatment (64,154) (B-3B) (Table 9). 
THe RoLe oF INTRAoPeRATIVe SeRum PTH 
meASuRemeNTS
Intraoperative monitoring of serum PTH (IOPTH) is 
often used during MIP for PHPT. Serum PTH is mea-
sured after induction of anesthesia but prior to skin inci-
sion and 10 minutes after removal of the enlarged gland 
(156). If the postoperative PTH levels does not fall by 
> 50%, into the normal range, persistent disease must 
be suspected. In the Ohe and cols. study on 109 pa-
tients (33 with PHPT and 76 with hyperparathyroidism 
secondary to renal disease) IOPTH changes correlated 
with cure of the disease (157) (C-4). Despite the wides-
pread use of the IOPTH approach, some studies have 
suggested its use only in selected patients (158) (C-4). 
A prospective study of 361 patients undergoing MIP 
for PHPT aimed to determine whether IOPTH can be 
optimized by limiting its application to patients with 
non-conclusive preoperative localization. All patients 
underwent technetium-99m sestamibi scintigraphy and 
ultrasonography. IOPTH was only used for decision-
-making in patients with negative scintigraphy and posi-
tive ultrasound results. Patients with any positive locali-
zation procedure (91%) were offered MIP. The success 
rate was 99%. The multiglandular disease rate was 3% 
in sestamibi-positive and 36% by sestamibi-negative (p 
< 0.0001). Both ultrasound and sestamibi scintigraphy 
had the same sensitivity (80% x 85%). Among patients 
with negative sestamibi, 71% of those who underwent 
MIP with IOPTH, had an inadequate fall in PTH levels 
and this was highly predictive of multiglandular disease. 
The use of IOPTH increased the time length of surgery 
from 34 to 60 minutes (159) (C-4).
Barczynski and cols., in a comparative, retrospective 
non-randomized study, found that the routine use of 
IOPTH improved MIP cure rates (open or video-as-
sisted) compared to unilateral neck exploration guided 
by imaging without IOPTH. Furthermore, IOPTH 
had an additional value in the surgical decision for fu-
ture neck exploration, especially in the case of a single 
positive imaging study (158) (C-4). 
In a large multicenter study from Scandinavian on 
2,708 patients, imaging procedures for preoperative lo-
calization were performed in 1,831 patients (sestamibi 
scan in 54% and ultrasonography in 41%) and IOPTH in 
792 patients. Bilateral exploration was performed in 61%, 
focused PTx in 17% and unilateral exploration in 22%. 
In a multivariate logistic regression analysis, IOPTH 
increased cure rate (OR 1.70, CI 95% 1.14-2.53, p = 
0.0092). The risk of hypocalcemia decreased with the 
use of localization procedures (OR 0.56, 95% CI 0.43-
0.78, p = 0.0004) and IOPTH (OR 0.56 95% CI 0.39-
0.90, p = 0.0015) (160) (B-2C). On the other hand, 
a prospective randomized trial comparing endoscopic 
bilateral neck exploration with endoscopic MIP plus 
IOPTH, found no differences in effectiveness, operation 
time and costs between the procedures (161) (B-2B).
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meDICAL TReATmeNT
Pharmacological treatment can be indicated for those 
patients with contraindications to surgical treatment, 
those with surgical failure, or those with no current 
criteria for surgical treatment (162,163) (Table 10). 
The decision to employ a pharmacological approach 
de pends also upon the goal of treatment, to reduce the 
serum calcium level and/or to increase BMD.
Cinacalcet hydrochloride
Cinacalcet hydrochloride is a calcimimetic agent that 
binds to the calcium-sensing receptor (CaR) of para-
thyroid cells, resulting in diminished PTH secretion 
(163). A multicenter, randomized, double-blind, pla-
cebo-controlled study on 78 patients with PHPT, eva-
luated the long-term effect of oral cinacalcet on serum 
calcium and PTH levels. The primary endpoint was the 
normalization of serum calcium (< 10.3 mg/dL) with a 
reduction of at least 0.5 mg/dL from baseline. Patients 
initially received cinacalcet 30 mg twice daily and this 
dose was increased to 40-50 mg twice daily for 12 weeks. 
Normal serum calcium concentrations were achieved in 
73% of patients during the maintenance phase, but se-
rum PTH decreased by only 7.6% after the same period 
(164). Serum calcium levels remained normal and PTH 
remained below baseline for up to 52 weeks (A-1B). The 
extension of the same study for 5 years showed that the 
normalization of serum calcium levels was maintained in 
approximately 80% of patients. Mean serum PTH levels 
remained stable (165). There were no significant chan-
ges in BMD. Oddly, bone turnover markers (serum bone 
alkaline phosphatase and urinary N-telopeptide) increa-
sed significantly as compared to placebo (164) (A-1B).
Cinacalcet is generally well-tolerated. The most 
common side effects are nausea (28%) and headache 
(23%) (164,166) (A-1B). These side effects appear to 
be dose-dependent. 
Hormone replacement therapy
A 2-year, randomized, double-blind, placebo-control-
led study on 42 postmenopausal women with mild 
PHPT, evaluated the effects of conjugated estrogen 
0.625 mg/day combined with medroxyprogesterone 
5 mg/day versus placebo on BMD and biochemical 
markers of bone turnover and calcium metabolism. 
Alkaline phosphatase activity decreased by 22%, urinary 
hydroxyproline excretion by 38%, N-telopeptide excre-
tion decreased by 60% and urinary calcium excretion by 
33% at the end of the study (144). Likewise, there were 
significant increases in total body, lumbar spine, femur 
neck and forearm BMD (144) (A-1B). These effects 
were maintained for at least 4 years in the extension 
study (167) (B-2B).
Selective modulators of estrogen receptors
A small study of only 18 patients tested raloxifene 60 
mg/day to reduce the serum calcium concentration in 
a double-blind, randomized, placebo-controlled study. 
After only 8 weeks, serum calcium and bone turnover 
markers (serum NTX and osteocalcin) were reduced. Af-
ter 4 weeks of discontinuation, no changes in serum cal-
cium and PTH levels were observed, and bone turnover 
markers returned to their baseline values (168)  (B-2B).
Bisphosphonates
Data from randomized controlled studies have con-
sistently demonstrated that oral alendronate decreases 
bone turnover and increases BMD in patients with mild 
PHPT, although the effects on serum calcium have 
been inconsistent (169-171) (A-1B). 
A randomized, double-blind, placebo-controlled 
study evaluated 40 postmenopausal women with PHPT 
who were randomized to receive alendronate 10 mg/
day or placebo for 48 weeks and followed for another 
24 weeks after withdrawal of treatment. BMD was sig-
nificantly higher in patients treated with alendronate (+ 
4.17 ± 6.01% vs. -0.25 ± 3.35% at the femoral neck, 
p = 0.011) and (+ 3.79 ± 4.04% vs. +0.19 +/- 2.8% 
at the lumbar spine, p = 0.016). Mean serum calcium 
levels decreased slightly in the alendronate group, but 
not in the placebo group. Bone turnover markers also 
decreased in patients treated with alendronate. There 
Table 10. Medical treatment and the effects on bone
Treatment BmD1 BTm2 Serum calcium Serum PTH3 Level of evidence 
Cinacalcet hydrochloride No change Increases Decreases to normal often Decreases slightly 1B
Conjugated estrogen + medroxyprogesterone Increases Decreases No change No change 1B
Raloxifene NA4 Decreases Decreases Decreases 1B
Alendronate Increases Decreases No change No change 1B
1 BMD: bone mineral density; 2 BTM: bone turnover markers; 3 PTH: parathyroid hormone; 4 NA: not available.
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were no significant differences in BMD at the distal 
1/3 radius in 48 weeks between the two groups (170) 
(A-1B).
In another multicenter, randomized, double-blind, 
placebo-controlled trial on 44 patients, treatment with 
alendronate over 2 years was associated with a signifi-
cant increase in BMD at the lumbar spine in compari-
son with the baseline. Total hip BMD was significantly 
increased in 1 year and remained stable for 1 more year, 
and no significant differences in BMD at the distal ra-
dius were observed. After 1 year, patients receiving 
placebo, started on alendronate and similar changes 
in BMD were observed in the 2nd year. Bone turnover 
markers decreased with the use of alendronate and se-
rum PTH, phosphate and ionized calcium levels did 
not change during the study (171) (A-1B).
In another randomized, placebo-controlled study, 
the effects of treatment with oral alendronate, 10 mg/
day or placebo, on BMD and biochemical markers of 
calcium and bone metabolism in elderly women with 
osteoporosis and mild PHPT were evaluated. Alen-
dronate was significantly associated with a decrease in 
bone turnover markers and an increase in BMD by 8.6 
± 3.0% at the lumbar spine, 4.8 ± 3.9% at total hip and 
1.2 ± 1.4% at total body, after 2 years. Serum calcium 
and phosphate and urinary calcium excretion decreased 
significantly during the first 3-6 months. A significant 
increase in serum PTH was seen during the first year of 
treatment (169) (B-2B).
SummARY AND CoNCLuSIoN
Primary hyperparathyroidism continues to be an evol-
ving disease in which several clinical profiles may be 
found. Most patients present with hypercalcemia in the 
asymptomatic form as an outpatient. Additional data 
on non-skeletal, non-classical manifestations such as 
fatigue, depression, decreased quality of life, diabetes 
and cardiovascular diseases, emerged in the literature 
during the last decade, but continue to be controver-
sial if a casuality really exists. Normocalcemic primary 
hyperparathyroidism constitutes an additional challen-
ge to the field as preliminary data suggest that it may 
progress with complications such as kidney stones wi-
thout exhibiting hypercalcemia. The diagnosis is usu-
ally made by routine measurements of serum calcium 
during medical examination along with a high or ina-
ppropriate normal serum PTH levels. Normocalcemic 
primary hyperparathyroidism is usually detected with 
routine serum PTH measurements during an osteopo-
rosis workup providing that secondary causes of an ele-
vated serum PTH are excluded. The definite treatment 
for PHPT is parathyroidectomy and in hypercalcemic 
patients in whom the parathyroid lesion is not detected 
by imaging procedures, some surgical criteria have been 
employed to select those candidates. For those patients 
who present with contraindications for surgery or re-
fuse the surgical procedure medical treatment can be 
an alternative. Cinacalcet, estrogen or bisphosphonates 
may be used in order to control serum calcium levels 
and to protect the skeleton. 
Disclosure: no potential conflict of interest relevant to this article 
was reported.
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